首页> 外国专利> Method to reduce or inhibit the progression of fatigue level in patients with Multiple Sclerosis and to provide neuroprotection laquinimod which comprises administering orally or a Salt thereof; laquinimod to reduce the level of fatigue, improve the functional State and deliver neuropro Protection in multiple sclerosis.

Method to reduce or inhibit the progression of fatigue level in patients with Multiple Sclerosis and to provide neuroprotection laquinimod which comprises administering orally or a Salt thereof; laquinimod to reduce the level of fatigue, improve the functional State and deliver neuropro Protection in multiple sclerosis.

机译:减少或抑制多发性硬化症患者的疲劳程度发展并提供神经保护性拉喹莫德的方法,该方法包括口服给药或其盐。拉喹莫德可减轻疲劳程度,改善功能状态并在多发性硬化症中提供Neuropro保护。

摘要

The subject invention provides methods for reducing or inhibiting progression of the level of fatigue in a multiple sclerosis human patient, for improving or inhibiting deterioration of the functional status of a multiple sclerosis human patient, and for improving or inhibiting deterioration of the general health of a multiple sclerosis human patient, comprising orally administering to the human patient laquinimod or a pharmaceutically acceptable salt thereof. The subject invention also provides a method for providing neuroprotection to a human subject, the method comprising orally administering to the human subject laquinimod or a pharmaceutically acceptable salt thereof.
机译:本发明提供了用于减少或抑制多发性硬化人类患者的疲劳水平的进展,改善或抑制多发性硬化人类患者的功能状态的恶化,以及改善或抑制多发性硬化人类患者的总体健康的恶化的方法。多发性硬化症的人类患者,包括口服给予拉喹莫德或其药学上可接受的盐。本发明还提供了一种向人类受试者提供神经保护的方法,该方法包括向人类受试者口服拉喹莫德或其药学上可接受的盐。

著录项

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号